<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.</PublisherName>
				<JournalTitle>Asian Pacific Journal of Cancer Prevention</JournalTitle>
				<Issn>1513-7368</Issn>
				<Volume>10</Volume>
				<Issue>5</Issue>
				<PubDate PubStatus="epublish">
					<Year>2009</Year>
					<Month>05</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Lack of Influence of XRCC1 and XPD Gene Polymorphisms on Outcome of Platinum-based Chemotherapy for Advanced Non Small Cell Lung Cancers</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>859</FirstPage>
			<LastPage>860</LastPage>
			<ELocationID EIdType="pii">25024</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>1970</Year>
					<Month>01</Month>
					<Day>01</Day>
				</PubDate>
			</History>
		<Abstract>Purpose: Genetic polymorphisms of DNA repair genes are associated with differential enzyme activity andmay help explain interindividual differences in response rates after platinum-based chemotherapy for non smallcell lung cancers (NSCLCs). This study was conducted to assess relationships between X-ray repair crosscomplementing group1 (XRCC1) and xeroderma pigmentosum group D (XPD) genetic polymorphisms andoutcome in NSCLC patients. &lt;br/&gt;&lt;b&gt;Methods&lt;/b&gt;: From March 1, 2005 to December 31, 2008, the polymerase chainreaction-restriction fragment length polymorphism method was applied to evaluate genetic polymorphisms ofthe XRCC1 codon399 (Arg/Gln) and XPD codon751 (Lys/Gln) DNA repair genes in 108 patients with stage IIIBand IV NSCLCs treated with platinum-based chemotherapy in the Department of Chemotherapy of JiangsuCancer Hospital and Research Institute. &lt;br/&gt;&lt;b&gt;Results&lt;/b&gt;: Among the assessed NSCLC patients, the overall responserate of chemotherapy was 21.6%. No association was found with either of the genetic polymorphisms, althoughthe XRCC1 399Arg/Arg genotype was associated with a non-significant higher median survival time (29 monthsversus 21 months for the Arg/Gln genotype and 15 months for the Gln/Gln genotype, P=0.09). &lt;br/&gt;&lt;b&gt;Conclusion&lt;/b&gt;: Ourresults suggested no influence of the XRCC1 codon399 (Arg/Gln) and XPD codon751 (Lys/Gln) geneticpolymorphisms on treatment response and survival in advanced NSCLC patients with platinum-basedchemotherapy.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Non Small Cell Lung Cancer</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">platinum chemotherapy</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">DNA repair enzymes</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">genetic polymorphisms</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://journal.waocp.org/article_25024_e000d1dd34f6c14b05474f4bc44f33ce.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
